24 May, 2017
Vertex Pharmaceuticals Inc now has $29.60 billion valuation.
Since November 30, 2016, it had 0 insider buys, and 27 insider sales for $25.38 million activity. Manning And Napier Advsr Ltd Liability Corporation stated it has 1.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals had 36 analyst reports since July 31, 2015 according to SRatingsIntel.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.09. Vertex Pharmaceuticals Incorporated's Return on Equity (ROE) is 15.20%, measure their profitability and reveals how much profit they generate with the money their shareholders. The company had revenue of $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. During the same quarter in the prior year, the business earned $0.09 EPS. The firm's quarterly revenue was up 79.5% compared to the same quarter a year ago. Robert W. Baird reiterated a buy rating and set a $115.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, January 9th.
TRADEMARK VIOLATION NOTICE: "Mitsubishi UFJ Trust & Banking Corp Has $71.922 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)" was first published by BBNS and is owned by of BBNS.
Among 17 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 10 have Buy rating, 0 Sell and 7 Hold. Oppenheimer Holdings Inc. restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Sunday, April 30th. The rating was maintained by Stifel Nicolaus with "Buy" on Thursday, January 26. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. The stock now has an average rating of Buy and an average price target of $114.53.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.66% during midday trading on Wednesday, reaching $114.60. The average volume stands around 1.89 million shares. $335,175 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Arbuckle Stuart A. The insider Sachdev Amit sold $673,733. As per Wednesday, March 29, the company rating was upgraded by BMO Capital Markets.
The stock's 50 day moving average is 115.88 and its 200 day moving average is 93.33. If you are reading this news story on another website, it was stolen and reposted in violation of USA and worldwide trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/05/23/vertex-pharmaceuticals-incorporated-vrtx-rating-reiterated-by-morgan-stanley.html. 8,979 shares were sold by Chodakewitz Jeffrey, worth $1.09M on Tuesday, May 2. The stock was sold at an average price of $119.50, for a total transaction of $18,785,400.00. Following the transaction, the chief marketing officer now owns 131,490 shares of the company's stock, valued at approximately $15,916,864.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 1,688 shares of the company's stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $107.63, for a total value of $8,664,215.00. Following the completion of the sale, the chief executive officer now directly owns 395,152 shares in the company, valued at approximately $47,220,664. The disclosure for this sale can be found here. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. Finally, Norinchukin Bank The boosted its stake in Vertex Pharmaceuticals by 7.3% in the first quarter. World Asset Management Inc now owns 24,259 shares of the pharmaceutical company's stock worth $2,116,000 after buying an additional 467 shares in the last quarter. Korea Investment has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 292 shares. Virtus ETF Advisers LLC now owns 6,814 shares of the pharmaceutical company's stock valued at $594,000 after buying an additional 859 shares during the period. Great West Life Assurance Co. Finally, Advantus Capital Management Inc boosted its position in Vertex Pharmaceuticals by 1.5% in the third quarter. Capital One National Association now owns 3,333 shares of the pharmaceutical company's stock worth $291,000 after buying an additional 90 shares in the last quarter. Oakmont Partners LLC bought a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $219,000. Companies may issue new shares and buy back their own shares.
Dekabank Deutsche Girozentrale decreased Vertex Pharmaceuticals Inc (VRTX) stake by 7.3% reported in 2016Q4 SEC filing.
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases.
